NCT03307941撤回1 期
Assessment of Metabolic and Pathological Response to Treatment With RCT and ImT Before Surgery in Locally Advanced Esophageal and Gastro-esophageal Junction Cancer: ARTemIS-Eso, a Three-level, Open-label, Phase I-II Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Phase I: determine the feasibility to administer monalizumab
研究概览
简要总结
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT administered prior to surgery.
详细描述
This study is indicated to patients with adenocarcinomas of the esophagus or gastro-esophageal junction and squamous cell carcinoma of the esophagus.
The study consists of 2 parts:
Phase I of the study is composed of the 3 following levels, corresponding to changes in the schedule and the number of administrations of monalizumab:
Level 1: monalizumab (ImT) administration starts 2 weeks after the end of RCT (Total of 3 ImT doses). A maximum of 7 days delay is allowed.
Level 2: monalizumab administration starts directly at the end of RCT (Total of 4 ImT doses). The first dose of monalizumab should be given on the following working day after the last radiotherapy administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old
- •ECOG performance status ≤ 1
- •Female and Male
- •Must have histologically confirmed esophageal ADC or SCC or gastro-esophageal junction ADC (Siewert I and II) eligible for a curative intent resection (recommended exploration by EUS and diagnostic laparoscopy in gastro-esophageal junctions) without restriction in age and sex and candidate for neoadjuvant RCT.
- •At least classified clinical T3Nx or any T, N+ according to cTNM version
- •Negative serum pregnancy test (for women of childbearing potential) within 7 (+/-1) days prior to the beginning of treatment.
- •Women of childbearing potential must agree to use one highly effective method of contraception at study entry (if this is not already the case, put in place within 1 week after ICF signature, and at the very latest before 1st administration of study treatment), during the study treatment administration and at least 5 months after the last administration of study treatment.
- •Men must agree to use condom during the course of this study and for at least 5 months after the last administration of the study treatment.
- •Adequate bone marrow function as defined below:
- •Absolute neutrophil count ≥1500/µL or 1.5x109/L
- •Hemoglobin ≥ 9 g/dL
- •Platelets ≥100000/µL or 100x109/L
- •Adequate liver function as defined below:
- •Serum total bilirubin ≤ 1.5 x ULN. In case of known Gilbert's syndrome < 3xUNL is allowed
- •AST (SGOT)/ALT (SGPT) ≤ 2.5 x ULN
- •Alkaline phosphatase ≤ 2.5 x ULN
- •Adequate renal function as defined:
- •Creatinine ≤ 1.5 x UNL or creatinine clearance >60 mL/min
- •Participants must have normal cardiac and pulmonary functions defined with ultrasonography (LVEF>50%) and pulmonary function tests (including DLCO (diffusing capacity factor of the lung for carbon monoxide)).
- •Completion of all necessary screening procedures within 28 days prior to enrolment.
- •Accessible tumour for biopsies through upper gastro-intestinal endoscopy (for translational research activities).
- •Signed Informed Consent form (ICF) obtained prior to any study related procedure and study treatment.
- •For the phase II expansion cohort only, significant FDG uptake at the primary tumour on baseline PET/CT, performed not more than 7 days before the beginning of the first course of CT, defined as SUVmax > 2x the mean liver uptake.
排除标准
- •Subjects meeting one of the following criteria are not eligible for this study:
- •Patient ineligible for curative intent surgery:
- •T4 with involvement of mediastinal structures as tracheobronchial, recurrent nerve, aorta over 90° of its circumference, vertebral body
- •Tumour ≥ 4cm in diameter developed above the carina
- •Visceral metastasis
- •Metastatic lymph nodes: supraclavicular and/or lombo-aortic
- •Cervical esophageal cancer defined as a tumor involving the lower border of the cricoid cartilage (at the level of the sixth cervical vertebra) to the thoracic inlet 5cm down under, generally between 18 and 20 cm from the dental arcade
- •Uncontrolled concurrent illness or any significant disease that, in the investigator's opinion, would exclude the patient from the study.
- •Absolute contraindication for surgery: respiratory failure (VEMS < 1000mL), weight loss> 20%, renal failure: creatinine > 1.5 ULN, myocardial infarct < 6 months, evolutive cardiopathy, ECOG 3 and 4, non-compensated cirrhosis.
- •Pregnant and/or lactating women.
- •Uncontrolled diabetes.
- •Individuals with a history of a different malignancy within the last 5 years are ineligible except cervical cancer in situ, and early stage basal cell or squamous cell carcinoma of the skin.
- •Patients with active, known or suspected autoimmune disease or condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive systemic treatment.
- •(Exception: patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring immunosuppressive systemic treatment, or conditions not expected to recur in the absence of an external trigger, are permitted to be enrolled.
- •Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active/autoimmune disease.
- •Patients with diseases known for hypersensitivity to radiotherapy.
- •Prior treatment for esophageal cancer: surgery, radiotherapy, chemotherapy or immunotherapy (in particular but not limited to anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including prior therapy with anti-tumour vaccines or other immuno-stimulatory anti-tumour agents.
- •Positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (ribonucleic acid or HCV antibody) indicating acute or chronic infection.
- •Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •History of allergy to study drug components or excipients.
- •Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.
研究组 & 干预措施
Single arm (classic 3+3 design)
Other
干预措施: Monalizumab (Drug)
Single arm (classic 3+3 design)
Other
干预措施: Oxaliplatin (Drug)
Single arm (classic 3+3 design)
Other
干预措施: 5-Fluorouracil (Drug)
Single arm (classic 3+3 design)
Other
干预措施: Metabolic (Other)
Single arm (classic 3+3 design)
Other
干预措施: Surgery (Procedure)
结局指标
主要结局
Phase I: determine the feasibility to administer monalizumab
时间窗: From date of randomization until the date of first documented disease recurrence, assessed up to 28 months
Successful and safe administration of the combination of radio-chemotherapy and at least 2 doses of immunotherapy
Phase II: pCR rate
时间窗: At date of surgery, assessed at 16 weeks post randomization
Defined by the absence of any tumoral cells on the surgical specimen post esophagectomy
次要结局
- Phase I: pCR rate(At date of surgery, assessed at 16 weeks post randomization)
- Phase I: DFS and OS at 2 years after surgery(From date of randomization until the date of first documented event, assessed up to 28 months)
- Phase I: Human Anti-Human Antibodies against monalizumab (HAHA) in serum(Week 5 to 3 months post surgery)
- Phase II: Two year-disease free survival (DFS) and two year-overall survival (OS)(2 years after the date the last patient had his surgery provided the trial objectives have been met)
- Phase II: Toxicity profile according to CTCAE v.4.03(From date of randomization until the date of first documented event, assessed up to 28 months)
- Phase II: Metabolic response after 1 course of CT and before surgery(from week 1 up to the time of surgery)
- Phase II: Number of the tumour-infiltrating lymphocytes (TILs)(at baseline, after 1 course of CT at week 3 and after surgery at 16 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous LeukemiaMyelogenous Leukemia, AcuteNCT01773408Hoffmann-La Roche122
终止
1 期
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) PatientsCastrate Resistant Prostate CancerNCT01352208Astellas Pharma Inc13
终止
1 期
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid TumorsNeoplasmsNCT01065623Bayer2
已完成
1 期
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)Leukemia, Myeloid, AcuteNCT03315039Moleculin Biotech, Inc.7
已完成
1 期
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)Leukemia, Myeloid, AcuteNCT03388749Moleculin Biotech, Inc.20